Table 2.
Sex-Wise Geometric Means With Univariate and Adjusted GMRs With 95% CIs Comparing the Cmax vs the AUC0-6 of Anti-TB Drugs in the Prospective Cohort, Pune, India
| Drug, Phase, and Parameter | Sex-Wise Geometric Mean Value |
GMR |
||||
|---|---|---|---|---|---|---|
| Men (n = 151) | Women (n = 72) | GMR (95% CI) | P Value | Adjusted GMR (95% CI)a | P Value | |
| Rifampin | ||||||
| Intensive phase | ||||||
| Cmax, μg/mL | 4.09 (3.45-4.85) | 4.26 (3.34-5.45) | 1.02 (0.75-1.38) | .92 | 1.04 (0.76-1.42) | .24 |
| AUC0-6, μg•h/mL | 13.80 (11.55-16.50) | 14.99 (11.87-18.91) | 1.09 (0.81-1.45) | .58 | 1.09 (0.81-1.46) | .57 |
| Continuation phase | ||||||
| Cmax, μg/mL | 3.72 (3.08-4.49) | 3.34 (2.46-4.53) | 0.96 (0.66-1.39) | .81 | 1.01 (0.71-1.44) | .97 |
| AUC0-6, μg•h/mL | 11.92 (9.64-14.73) | 12.53 (8.82-17.80) | 1.05 (0.70-1.57) | .81 | 1.09 (0.75-1.60) | .65 |
| Isoniazid | ||||||
| Intensive phase | ||||||
| Cmax, μg/mL | 6.44 (5.53-7.52) | 8.38 (6.77-10.38) | 1.3 (1.0-1.68) | .046 | 1.29 (1.0-1.68) | .047 |
| AUC0-6, μg•h/mL | 23.24 (19.88-27.17) | 31.67 (26.23-38.24) | 1.36 (1.07-1.7) | .012 | 1.36 (1.07-1.73) | .012 |
| Continuation phase | ||||||
| Cmax, μg/mL | 6.85 (5.61-8.37) | 8.93 (7.30-10.93) | 1.30 (0.99-1.72) | .063 | 1.29 (0.98-1.70) | .072 |
| AUC0-6, μg•h/mL | 24.67 (20.48-29.72) | 36.23 (29.71-44.17) | 1.47 (1.12-1.92) | .005 | 1.46 (1.12-1.90) | .005 |
| Pyrazinamide | ||||||
| Intensive phase | ||||||
| Cmax | 26.55 (22.93-30.74) | 29.44 (23.27-37.25) | 1.11 (0.84-1.46) | .46 | 1.04 (0.80-1.36) | .78 |
| AUC0-6, μg•h/mL | 97.01 (82.31-114.35) | 112.97 (86.81-147.03) | 1.16 (0.86-1.58) | .33 | 1.09 (0.81-1.47) | .57 |
a
The models are adjusted for age, sex, and glycated hemoglobin value. Visit 1 was during the intensive phase of TB treatment, while visit 2 took place during the continuation phase of TB treatment.
AUC = area under the curve; Cmax = maximum concentration; GMR = geometric mean ratio.